Chadwick Mills

Chad focuses on corporate and securities law, and he regularly acts as outside securities and corporate governance counsel to public life sciences companies. Chad provides ongoing compliance and strategic advice to biotechnology, pharmaceutical and device companies and their boards of directors on a range of securities, corporate and investor outreach matters, including financial reporting and disclosure issues, shareholder engagement and activism, securities offerings, and corporate governance matters – in each case based on his extensive experience in the public life sciences space.

Chad has worked with or served as primary outside counsel to numerous current and former public life sciences clients, including ACELYRIN, Alkermes, Alumis, AcelRx Pharmaceuticals, BioMarin Pharmaceutical, Cardica, Cerus Corporation, Conor Medsystems, Cytokinetics, Exelixis, Five Prime Therapeutics, Geron, GTx, Harpoon Therapeutics, Horizon Therapeutics, InterMune, Jazz Pharmaceuticals, Kosan Biosciences, Kronos Bio, Lyell Immunopharma, Medivation, Molecular Devices, NGM Biopharmaceuticals, Rigel Pharmaceuticals, Sangamo Therapeutics, Seagen, Tercica, Threshold Pharmaceuticals, Volcano and XenoPort.

Chad’s representative transactions include advising:

• Jazz Pharmaceuticals – Rule 144A offerings of $1 billion 2% exchangeable senior notes due 2026, $575 million 1.5% exchangeable senior notes due 2024 and $575 million 1.875% exchangeable senior notes due 2021
• Seagen – Public offering of $690 million of common stock to finance the acquisition of Cascadian Therapeutics and a subsequent public offering of $552 million of common stock
• BioMarin Pharmaceutical – Public offering of $720 million of common stock
• Sangamo Therapeutics – Private offering to Biogen of $225 million of common stock in connection with a collaboration agreement
• Tercica – Concurrent private offering to Ipsen of $77 million of common stock, a $25 million convertible note, a second 30-million-euro convertible note and a third $15 million convertible note in connection with a collaboration agreement
• ACELYRIN – Initial public offering (IPO) of $621 million of common stock
• Lyell Immunopharma – IPO of $425 million of common stock
• Kronos Bio – IPO of $288 million of common stock